{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:45:40Z","timestamp":1793832340528,"version":"4.6.1"},"reference-count":24,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2007,6,26]],"date-time":"2007-06-26T00:00:00Z","timestamp":1182816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:p>To determine whether bodyweight (BW) loss, daily urine volume (UV) or furosemide use are associated with cisplatin nephrotoxicity, performance status, serum chemistries before treatment, average daily UV, maximum BW loss and use of furosemide on days 1\u20135 of chemotherapy were evaluated retrospectively in chemotherapy\u2010naive patients with thoracic malignancies who had received 80\u00a0mg\/m<jats:sup>2<\/jats:sup> cisplatin. Associations between these parameters and the worst serum creatinine levels (group 1, grade 0\u20131; and group 2, grade 2\u20133) during the first cycle were evaluated. Of the 417 patients (327 men and 90 women; median age, 59\u00a0years), 390 were categorized into group 1 and 27 were categorized into group 2. More women and older patients were observed in group 2 than in group 1 (11.1 <jats:italic>vs<\/jats:italic> 5.2%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.044, and 65 <jats:italic>vs<\/jats:italic> 59\u00a0years, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.041, respectively). The median average daily UV was 3902\u00a0mL in group 1 and 3600\u00a0mL in group 2 (<jats:italic>P\u00a0=<\/jats:italic>\u00a00.021). A maximum BW loss\u00a0\u22652.1\u00a0kg was noted in 4.4% of patients in group 1 and 18.5% of patients in group 2 (<jats:italic>P\u00a0=<\/jats:italic>\u00a00.006). Furosemide was used in 206 (49.4%) patients. The median total dose of furosemide in groups 1 and 2 were 0\u00a0mg and 26\u00a0mg, respectively (<jats:italic>P\u00a0=<\/jats:italic>\u00a00.024). A multivariate analysis showed that a maximum BW loss \u22652.1\u00a0kg and the total furosemide dose were significantly associated with group category. In conclusion, BW loss and total furosemide dose were associated with cisplatin nephrotoxicity. (<jats:italic>Cancer Sci<\/jats:italic> 2007; 98: 1408\u20131422)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2007.00532.x","type":"journal-article","created":{"date-parts":[[2007,6,27]],"date-time":"2007-06-27T06:56:43Z","timestamp":1182927403000},"page":"1408-1412","source":"Crossref","is-referenced-by-count":13,"title":["Bodyweight change during the first 5\u00a0days of chemotherapy as an indicator of cisplatin renal toxicity"],"prefix":"10.1111","volume":"98","author":[{"given":"Ikuo","family":"Sekine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nokihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Kunitoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohide","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,6,26]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"344","volume-title":"Cancer: Principles and Practice of Oncology","author":"Johnson SW","year":"2005"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.409"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.109"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.077"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1993.1184"},{"key":"e_1_2_6_7_2","first-page":"2836","volume-title":"The Kidney","author":"Walker RJ","year":"2000"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600884"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050661"},{"key":"e_1_2_6_10_2","first-page":"1629","volume-title":"Avery's Drug Treatment","author":"Taeschner W","year":"1997"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8223(99)00048-6"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197704)39:4<1372::AID-CNCR2820390404>3.0.CO;2-J"},{"key":"e_1_2_6_13_2","first-page":"367","article-title":"Phase I study of high\u2010dose cis\u2010dichlorodiammineplatinum (II) with forced diuresis","volume":"61","author":"Chary KK","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_6_14_2","first-page":"31","article-title":"Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study","volume":"66","author":"Al\u2010Sarraf M","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_6_15_2","first-page":"73","article-title":"High\u2010dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity","volume":"65","author":"Ostrow S","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-003-0620-1"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/28.8.463"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1200\/JCO.1994.12.10.2121","article-title":"Renal tolerance of cisplatin in patients more than 80 years old","volume":"12","author":"Thyss A","year":"1994","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/21.3.202"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200104000-00018"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686298"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.17.3733"},{"key":"e_1_2_6_23_2","first-page":"169","article-title":"Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity","volume":"67","author":"Campbell AB","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.2.304"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050548"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2007.00532.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2007.00532.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T04:50:13Z","timestamp":1697172613000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2007.00532.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,26]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1111\/j.1349-7006.2007.00532.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2007.00532.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,26]]}}}